Drugs / QH103 Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07491263 | May 2026 → Apr 2028 expected | B-cell acute lymphoblastic leukemia | Fujian Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QH103 Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491263 ↗ |
| Known as | QH103 cell infusion | “This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell infusion in subjects with CD19-positive R/R B-ALL.” NCT07491263 ↗ |
| Modality | Cell therapy | “Biological: CD19 CAR-γδT cell” NCT07491263 ↗ |
| Target | CD19 | “CD19 CAR-γδT cell” NCT07491263 ↗ |